AstraZeneca Pharma India Limited

AstraZeneca Pharma India Limited

AstraZeneca Pharma India Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 10, 2026. The meeting will be held through Video Conferencing (VC)/Other Audio Visual Means (OAVM) to transact the following business: to receive, consider and adopt the Audited Financial Statements of the Company for the financial year ended March 31, 2026 and the Reports of the Board of Directors and Auditors thereon. Other agenda items include the re-appointment of Ms. Shilpa Divekar Nirula as an Independent Director, the declaration of a dividend of Rs. 36/- per share on equity shares for the financial year 2025-26, and the appointment of a Director in place of Ms. Bhavana Agrawal (DIN: 10485441) who retires by rotation.

AstraZeneca Pharma India Limited

AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organization to import and market Benralizumab 30 mg/ml solution for injection in pre-filled syringe (Fasenra) for an additional indication, Hypereosinophilic Syndrome (HES) in patients aged 12 years and older.

AstraZeneca Pharma India Limited

AstraZeneca Pharma India Limited has informed the Exchange about the appointment of Senior Management Personnel (SMP) as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The appointments include Mr. Mihir Parikh as Director - Commercial Excellence, BD & Strategy, Mr. Vinay Sharma as Director - Rare Diseases Business Unit, and Mr. Amay Ashok Pandey as Director – Oncology Business Unit.